MAPLE GROVE, Minn., Aug. 29, 2013 /PRNewswire/ -- Upsher-Smith Laboratories, Inc., today announced its Morphine Sulfate Extended-Release Capsules, CII will be commercially available on September 4, 2013.
Historically, there have been a limited number of morphine sulfate generics available. Upsher-Smith used its extensive formulation experience to overcome the challenges presented.
Upsher-Smith's family of Morphine Sulfate Extended-Release Capsules, CII includes seven dosage strengths: 10 mg, 20 mg, 30 mg, 50 mg, 60 mg, 80 mg, and 100 mg. This will be the first generic entrant for the 10-mg extended-release capsule dosage strength.1 Upsher-Smith's generic drug segment is dedicated to providing high-quality pharmaceutical products that are affordable and accessible to patients.
Upsher-Smith is an independent specialty pharmaceutical company dedicated to its mission of Advancing Pharmacotherapy to Improve Life™. Upsher-Smith currently leverages its core strength in formulation development to drive both branded and generic therapeutic solutions to address patients' needs ranging in scope from women's health to cardiology. The Company has a particular focus on developing therapies for people living with challenging central nervous system conditions like epilepsy, and has an emerging neurology pipeline with three products in clinical development. For more information, visit www.upsher-smith.com.
Please see Full Prescribing Information, including Boxed Warning, at http://www.upsher-smith.com/wp-content/uploads/MorphineSulfate_MI.pdf.
1. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. http://www.accessdata.fda.gov/scripts/cder/ob/docs/tempai.cfm. Accessed May 9, 2013.
SOURCE Upsher-Smith Laboratories, Inc.